Mark Pegram, MD

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    Novartis
    Topic:
    Consultant
    Date added:
    04/07/2022
    Date updated:
    01/08/2024
    Relationship end date:
    12/31/2024
  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    Gilead
    Topic:
    Consultant
    Date added:
    04/10/2023
    Date updated:
    01/08/2024
    Relationship end date:
    12/31/2024
  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    Roche/Genentech
    Topic:
    Consultant
    Date added:
    01/08/2024
    Date updated:
    01/08/2024
    Relationship end date:
    12/31/2024
  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    Astra-Zeneca/Daiichi Sankyo
    Topic:
    Consultant
    Date added:
    01/08/2024
    Date updated:
    01/08/2024
    Relationship end date:
    12/31/2024
Return to 4th Binaytara Precision Oncology Summit: Current Standards and Emerging Therapies